Allarity Therapeutics develops cancer treatments, mainly stenoparib, and a companion diagnostic test to identify patients likely to benefit from them. ALLR reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 16 | Ascendiant Capital | Target raised | Buy | |
| Jun 8 | Ascendiant Capital | Maintained | Buy |
Seasonality
How ALLR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ALLR in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLR is in one of them and how their past ALLR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALLR in an article yet. Here's the latest on the wider market.
About Allarity Therapeutics
Allarity Therapeutics is a pharmaceutical company based in Boston, Massachusetts, that develops cancer treatments. Its main focus is stenoparib, a therapy being studied in ovarian cancer and small cell lung cancer. The company also develops its Drug Response Predictor platform, a companion diagnostic designed to identify which patients are most likely to benefit from a particular cancer drug.
- Headquarters
- Boston, MA